Tenet Healthcare (NYSE:THC) Stock Rating Lowered by Wall Street Zen

by · The Markets Daily

Tenet Healthcare (NYSE:THC – Get Free Report) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

THC has been the subject of several other research reports. Wells Fargo & Company boosted their target price on shares of Tenet Healthcare from $231.00 to $281.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Guggenheim boosted their price objective on Tenet Healthcare from $242.00 to $283.00 and gave the company a “buy” rating in a report on Tuesday, July 28th. TD Cowen upped their price objective on Tenet Healthcare from $233.00 to $263.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tenet Healthcare in a research report on Monday, July 27th. Finally, UBS Group boosted their price target on Tenet Healthcare from $288.00 to $308.00 and gave the company a “buy” rating in a report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Tenet Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $273.00.

Read Our Latest Report on THC

Tenet Healthcare Stock Down 0.3%

Shares of NYSE THC opened at $267.23 on Friday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.35 and a current ratio of 1.41. Tenet Healthcare has a 1 year low of $157.58 and a 1 year high of $270.57. The stock’s 50-day simple moving average is $210.20 and its 200-day simple moving average is $204.03. The firm has a market cap of $21.52 billion, a price-to-earnings ratio of 10.31, a PEG ratio of 1.02 and a beta of 1.23.

Tenet Healthcare (NYSE:THC – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The company reported $6.12 EPS for the quarter, beating analysts’ consensus estimates of $4.26 by $1.86. The firm had revenue of $6.04 billion during the quarter, compared to the consensus estimate of $5.43 billion. Tenet Healthcare had a return on equity of 26.76% and a net margin of 10.27%.Tenet Healthcare’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.02 earnings per share. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. As a group, equities analysts anticipate that Tenet Healthcare will post 20.97 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Christopher S. Lynch sold 3,837 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $243.44, for a total transaction of $934,079.28. Following the completion of the transaction, the director owned 9,568 shares in the company, valued at approximately $2,329,233.92. This represents a 28.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director J Robert Kerrey sold 5,638 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $174.52, for a total transaction of $983,943.76. Following the completion of the sale, the director directly owned 16,804 shares in the company, valued at approximately $2,932,634.08. This trade represents a 25.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 41,375 shares of company stock worth $9,793,347 over the last 90 days. Insiders own 0.97% of the company’s stock.

Institutional Investors Weigh In On Tenet Healthcare

Several large investors have recently made changes to their positions in THC. Norges Bank bought a new position in Tenet Healthcare in the 4th quarter valued at about $248,494,000. Wellington Management Group LLP lifted its stake in shares of Tenet Healthcare by 1,114.2% in the 4th quarter. Wellington Management Group LLP now owns 1,135,801 shares of the company’s stock worth $225,706,000 after acquiring an additional 1,042,260 shares during the period. Manning & Napier Advisors LLC bought a new position in shares of Tenet Healthcare in the second quarter valued at approximately $168,761,000. Boston Partners increased its stake in shares of Tenet Healthcare by 38.8% during the third quarter. Boston Partners now owns 3,147,555 shares of the company’s stock valued at $638,958,000 after acquiring an additional 880,413 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Tenet Healthcare by 62.3% during the third quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock worth $380,989,000 after purchasing an additional 720,160 shares in the last quarter. Institutional investors and hedge funds own 95.44% of the company’s stock.

Key Headlines Impacting Tenet Healthcare

Here are the key news stories impacting Tenet Healthcare this week:

  • Positive Sentiment: An analyst boosted Tenet’s third-quarter EPS forecast, signaling improving expectations for the company’s near-term profitability. Q3 EPS Forecast for Tenet Healthcare Boosted by Analyst
  • Positive Sentiment: Zacks Research raised its Tenet EPS estimates across multiple periods: fourth-quarter 2026 EPS increased to $5.04 from $4.47, fiscal 2026 EPS to $20.32 from $17.52, fiscal 2027 EPS to $18.91 from $17.17, and fiscal 2028 EPS to $20.09 from $17.99. Quarterly estimates for Q2 2027, Q3 2027, Q4 2027 and Q2 2028 were also increased. Zacks maintained a “Strong-Buy” rating, supporting the bullish outlook for earnings growth.
  • Neutral Sentiment: The revised fiscal 2026 estimate of $20.32 remains below the broader analyst consensus of $21.07, suggesting that Zacks’ revisions are favorable but do not represent an across-the-board increase in expectations.
  • Neutral Sentiment: Wall Street Zen downgraded Tenet from “Strong Buy” to “Buy.” Although the stock remains positively rated, the change reflects somewhat less conviction and could limit the impact of the otherwise favorable earnings revisions. Wall Street Zen Downgrades Tenet Healthcare to Buy

About Tenet Healthcare

(Get Free Report)

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

Further Reading